Surmodics, Inc. announced new real-world results from the PROWL registry evaluating the company’s Pounce thrombectomy pl ...

Peripheral artery disease, or PAD, is a condition where the arteries become narrow or blocked over time, most often affecting ...

Surmodics, Inc. announced results from a sex-specific analysis of its ongoing PROWL registry evaluating real-world use of the ...

Vascular. 2005;13(2):84-91. The most common causes of injury in the present series were lacerations from either accidental, occupational, or road traffic injuries. Stab injuries and missile injuries ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care ...

Aug. 9, 2002 -- Injecting autologous bone marrow into the gastrocnemius of patients with ischemic limbs can significantly improve blood flow, tissue oxygenation, and symptoms, according to results of ...

A risk scoring system based on independent prognostic factors of mortality in patients with critical limb ischemia (CLI) shows good ability to predict 2-year life expectancy, according to a Japanese ...

Surmodics (Nasdaq:SRDX) announced results from a sex-specific analysis of real-world patients in a study of its Pounce ...

Following angioplasty, patients with critical limb ischemia (CLI) due to pure isolated infrapopliteal disease assigned antiplatelet therapy with a combination of aspirin and cilostazol experienced ...

Please provide your email address to receive an email when new articles are posted on . Use of vorapaxar, a PAR-1 antagonist, was associated with reduced acute limb ischemia in patients with ...

According to Coherent Market Insights (CMI), the global critical limb ischemia market size is projected to expand at a CAGR of 8.8%, growing from USD 5.55 Bn in 2025 to USD 10.02 Bn by 2032. Based on ...

Critical Limb Ischemia companies are Boston Scientific Corporation, AnGes, Inc., Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd ...